Publication Name	World Journal of Diabetes
Manuscript ID	10887
Country	Japan

Received	2014-04-24 20:38
Peer-Review Started	2014-04-24 22:35
To Make the First Decision	2014-05-14 13:37
Return for Revision	2014-05-20 20:48
Revised	2014-05-30 14:48
Second Decision	2014-11-21 12:06
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-12-01 13:49
Articles in Press	2014-12-01 13:49
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-01-15 16:06
Publish the Manuscript Online	2015-01-31 14:38

ISSN	1948-9358 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Review
Article Title	Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan
Manuscript Source	Invited Manuscript
All Author List	Tsuyoshi Ohkura
Funding Agency and Grant Number
Corresponding Author	Tsuyoshi Ohkura, MD, PhD, Assistant Professor, Division of Cardiovascular Medicine, Endocrinology and Metabolism, Department of Molecular Medicine and Therapeutics, Tottori University Faculty of Medicine, 36-1 Nishi-chou, Yonago, Tottori, Japan. ohkura@med.tottori-u.ac.jp
Key Words	Sodium-glucose cotransporter 2 inhibitor; Type 2 diabetes mellitus; Ipragliflozin; Japan
Core Tip	Ipragliflozin is highly selective for sodium-glucose cotransporter 2 (SGLT2) inhibitor. Twelve weeks of ipragliflozin 50 mg/d vs placebo decreased HbA1c and body weight by 0.65% and 0.66 kg, respectively, in Western patients, and by 1.3% and 1.89 kg, respectively, in Japanese patients. The highly selective SGLT2 inhibitor ipragliflozin improves glycemic control and reduces body weight, and lowers hypoglycemic risk and abdominal symptoms. Ipragliflozin has potential as a novel anti-diabetic and anti-obesity agent.
Publish Date	2015-01-31 14:38
Citation	Ohkura T. Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan. World J Diabetes 2015; 6(1): 136-144
URL	http://www.wjgnet.com/1948-9358/full/v6/i1/136.htm
DOI	http://dx.doi.org/10.4239/wjd.v6.i1.136

Full Article (PDF)	WJD-6-1.pdf
Full Article (Word)	WJD-6-1.doc
Manuscript File	10887-Review.doc
Answering Reviewers	10887-Answering reviewers.pdf
Conflict-of-Interest Disclosure Form	10887-Conflict-of-interest statement.pdf
Copyright License Agreement	10887-Copyright assignment.pdf
Peer-review Report	10887-Peer review(s).pdf
Scientific Misconduct Check	10887-CrossCheck.jpg
Scientific Editor Work List	10887-Scientific editor work list.pdf